Last reviewed · How we verify

Brinzolamide ophthalmic suspension

Sun Pharmaceutical Industries Limited · Phase 3 active Small molecule

Brinzolamide ophthalmic suspension is a Carbonic anhydrase inhibitor Small molecule drug developed by Sun Pharmaceutical Industries Limited. It is currently in Phase 3 development for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.

Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure. Used for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

At a glance

Generic nameBrinzolamide ophthalmic suspension
SponsorSun Pharmaceutical Industries Limited
Drug classCarbonic anhydrase inhibitor
TargetCarbonic anhydrase II
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Brinzolamide inhibits carbonic anhydrase II in the ciliary body of the eye, which decreases the secretion of aqueous humor. By reducing aqueous humor production, the drug lowers intraocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management. The ophthalmic suspension formulation allows direct topical delivery to the eye.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Brinzolamide ophthalmic suspension

What is Brinzolamide ophthalmic suspension?

Brinzolamide ophthalmic suspension is a Carbonic anhydrase inhibitor drug developed by Sun Pharmaceutical Industries Limited, indicated for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

How does Brinzolamide ophthalmic suspension work?

Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.

What is Brinzolamide ophthalmic suspension used for?

Brinzolamide ophthalmic suspension is indicated for Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Who makes Brinzolamide ophthalmic suspension?

Brinzolamide ophthalmic suspension is developed by Sun Pharmaceutical Industries Limited (see full Sun Pharmaceutical Industries Limited pipeline at /company/sun-pharmaceutical-industries-limited).

What drug class is Brinzolamide ophthalmic suspension in?

Brinzolamide ophthalmic suspension belongs to the Carbonic anhydrase inhibitor class. See all Carbonic anhydrase inhibitor drugs at /class/carbonic-anhydrase-inhibitor.

What development phase is Brinzolamide ophthalmic suspension in?

Brinzolamide ophthalmic suspension is in Phase 3.

What are the side effects of Brinzolamide ophthalmic suspension?

Common side effects of Brinzolamide ophthalmic suspension include Blurred vision, Ocular discomfort or irritation, Taste perversion, Headache.

What does Brinzolamide ophthalmic suspension target?

Brinzolamide ophthalmic suspension targets Carbonic anhydrase II and is a Carbonic anhydrase inhibitor.

Related